MYCN and neuroblastoma: The whole picture of PRMT1 in neuroblastoma cells without MYCN overexpression is likely to be much more complicated than what we showed in the SK-N-SH cells. Our data may partially explain clinical data showing that low PRMT1 expression is a poor prognostic factor in patients with non-MYCN-amplified neuroblastoma.